Skip to main content
. Author manuscript; available in PMC: 2019 Aug 1.
Published in final edited form as: Ann Rheum Dis. 2018 Apr 13;77(8):1187–1193. doi: 10.1136/annrheumdis-2017-212905

Table 3.

Risk Race/Ethnicity and Risk of Hospitalized Allopurinol-Associated Severe Cutaneous Adverse Reactions (AASCARs) according to Chronic Kidney Disease (CKD) and Initial Allopurinol Dose

Variable High-Risk Race/Ethnicity Low-Risk Race/Ethnicity
Initial Allopurinol Dose Risk of Hospitalized AASCARs (/1000 persons) Multivariable-Adjusted Relative Risk* Risk of Hospitalized AASCARs (/1000 persons) Multivariable-Adjusted Relative Risk*
CKD >100 mg/d 1.63 (0.60 to 3.55) 9.08 (3.58 to 22.77) 1.12 (0.36 to 2.60) 5.65 (2.10 to 15.22)
≤100 mg/d 0.78 (0.21 to 1.99) 4.10 (1.37 to 12.13) 0.72 (0.20 to 1.85) 3.62 (1.23 to 10.71)
No CKD >100 mg/d 1.14 (0.92 to 1.39) 5.86 (3.54 to 9.68) 0.25 (0.17 to 0.34) 1.32 (0.76 to 2.34)
≤100 mg/d 0.55 (0.38 to 0.78) 2.69 (1.51 to 4.79) 0.20 (0.12 to 0.32) 1.0 (reference)
*

Adjusted for age, and sex.